The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia

Rheumatic Disease Clinics of North America

Volumn 28, Issue 2, 2002, Pages 343-351

  Henriksson, Karl G ^a,b   Sörensen, Jan ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DEXTROMETHORPHAN; DIPHENHYDRAMINE; KETAMINE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; TRAMADOL; AMINO ACID RECEPTOR BLOCKING AGENT;

AGGRESSION; AMNESIA; ANALGESIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DYSARTHRIA; FIBROMYALGIA; GAIT DISORDER; GASTROINTESTINAL DISEASE; HUMAN; HYSTERIA; MOTOR DYSFUNCTION; NEUROLOGICAL COMPLICATION; NYSTAGMUS; PAIN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; SENSITIZATION; VERTIGO; DRUG ANTAGONISM;

DEXTROMETHORPHAN; EXCITATORY AMINO ACID ANTAGONISTS; FIBROMYALGIA; HUMAN; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; HUMANS;

EID: 0035990379     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(01)00013-8     Document Type: Review

References (32)

1. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee
2. Fibromyalgia
3. Pain and nociception in fibromyalgia: Clinical and neurobiological considerations on aetiology and pathogenesis
4. Pain mechanisms in fibromyalgia syndrome. A myologist's view
5. Contribution of central neuroplasticity to pathological pain: Review of clinical and experimental evidence
6. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states
7. Targeting the N-methyl-D-aspartate receptor for chronic pain management: Preclinical animal studies, recent clinical experience and future research directions
8. Intraplantar injection of dextromethorphan, ketamine or memantine attenuates formalin-induced behaviors
9. 'Balanced analgesia' in the perioperative period: Is there a place for ketamine?
10. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine and ketamine
11. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man
12. Codeine and its alternatives for pain and cough relief
13. Dependence on dextromethorphan hydrobromide
14. Clinical trials of NMDA-receptor antagonists as analgesics
15. Prolonged analgesic effect of ketamine, and N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain
16. The use of NMDA-receptor antagonists in the treatment of chronic pain
17. The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans
18. NMDA receptor blockade in chronic neuropathic pain: A comparison of ketamine and magnesium chloride
19. Successful treatment of postherpetic neuralgia with oral ketamine
20. The combination of oral morphine and ketamine improves pain relief in postherpetic neuralgia compared with morphine or ketamine alone. A randomised, double blind, placebo-controlled crossover comparison
21. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
22. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients
23. Fibromyalgia - Are there different mechanisms in the processing of pain?
24. Hyperexcitability in fibromyalgia
25. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients
26. Low-dose subcutaneous ketamine infusion and morphine tolerance
27. NMDA receptor antagonists: Interactions with opioids
28. Dextromethorphan attenuates and reverses analgesic tolerance to morphine
29. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions
30. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?
31. Supplemental dextromethorphan in the treatment of fibromyalgia. A double blind, placebo controlled study of efficicacy and side-effects